SCHEMBL5879133

SCHEMBL5879133

Cc1cccc2[nH]c3c4c(=O)[nH]c(=O)c4c4c(=O)[nH]c(=O)c4c3c12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 5/20 0.56
PARP1 P09874 4/20 0.45
KIF11 P52732 1/20 0.42
MEN1 O00255 1/20 0.41
MAPT P10636 1/20 0.41
KMT2A Q03164 1/20 0.41
DAO P14920 2/20 0.40
DDO Q99489 1/20 0.40
GABRP O00591 1/20 0.40
GABRD O14764 1/20 0.40
GABRA1 P14867 1/20 0.40
GABRB1 P18505 1/20 0.40
GABRG2 P18507 1/20 0.40
GABRB3 P28472 1/20 0.40
GABRA5 P31644 1/20 0.40
GABRA3 P34903 1/20 0.40
GABRA2 P47869 1/20 0.40
GABRB2 P47870 1/20 0.40
GABRA4 P48169 1/20 0.40
GABRE P78334 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5879190 0.80 CHEK1 (0.58) CHEK1PARP1DAOGABRPGABRD
SCHEMBL5879193 0.79 CHEK1 (0.56) CHEK1PARP1
SCHEMBL5879268 0.79 CHEK1 (0.56) CHEK1PARP1DAODDO
SCHEMBL5879257 0.79 CHEK1 (0.56) CHEK1
SCHEMBL5879195 0.79 CHEK1 (0.56) CHEK1PARP1DAODDO
SCHEMBL5879154 0.78 ABCG2 (0.53) CHEK1PARP1MEN1MAPTKMT2A
SCHEMBL6008331 0.76 GPR84 (0.48) PARP1KIF11MEN1MAPTKMT2A
SCHEMBL30715250 0.76 GPR84 (0.48) PARP1KIF11MEN1MAPTKMT2A
SCHEMBL22457403 0.76 PARP1 (0.40) CHEK1PARP1KIF11MEN1MAPT
SCHEMBL3125353 0.76 PARP1 (0.49) CHEK1PARP1DAODDOCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7151108-B2 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATORIES SERVIER (FR) 2006-12-19 US disclosed
EP-1411057-B1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2005-04-27 EP disclosed
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATOIRES SERVIER (FR) 2004-04-22 US disclosed
EP-1411057-A1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2004-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents XDH, TOP2A, TOP1 CHEK1 943/4885PARP1 120/4885KIF11 4327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.